通过导管大动脉干预后进行抗血栓治疗
Harish Sharma1, Shazia Afzal2, Jürgen Leick2
1Department of Cardiology, Queen Elizabeth Hospital Birmingham, Birmingham B15 2TH, UK; Institute of Cardiovascular Sciences, University of Birmingham, Birmingham B15 2TT, UK.
Pharmacology & therapeutics
|August 12, 2023
概括
过导管大动脉置换 (TAVR) 是大动脉狭窄的常见病例. 本综述检查了TAVR后的最佳抗血小板和抗凝策略,解决了指导方针的差异以及不同患者群体的最新证据.
科学领域:
- 心脏病学 心脏病学
- 干预心脏病学 干预心脏病学
- 心血管外科心血管外科
背景情况:
- 超导管大动脉置换 (TAVR) 的体积现在超过了美国针对症状性大动脉狭窄症的外科大动脉置换.
- 在TAVR后进行抗血栓治疗的现有国际指南早于最近的重大临床研究.
- 欧洲和美国的指导方针之间存在差异,这些指导方针在TAVR后对抗血栓瘤药物进行推.
研究的目的:
- 对TAVR后的抗血小板和抗凝固疗法的当前文献进行审查.
- 为临床医生提供针对不同患者群体量身定制的最佳抗血栓策略的指导.
- 由于最近的研究结果和指导方针变化,需要更新建议.
主要方法:
- 对TAVR后的抗血小板和抗凝治疗研究的文献综述.
- 从最近的临床试验和观察性研究中分析数据.
- 综合证据,以告知抗血栓性药物建议.
主要成果:
- 该审查综合了TAVR后使用的各种抗血小板和抗凝疗方案的数据.
- 研究了不同抗血栓策略的有效性和安全性的证据.
- 强调考虑影响治疗决策的患者特定因素.
结论:
- 在TAVR后最佳的抗血栓策略需要仔细考虑最近的证据和患者因素.
- 可能需要进一步的研究来完善指导方针,并针对特定的患者子组.
- 在TAVR治疗后协调抗血栓治疗的国际建议是合理的.
相关概念视频
Venous Thrombosis III: Interprofessional Care
10
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
10
Aortic Regurgitation III: Medical Management
25
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
25
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Atherosclerosis III: Management
12
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
12
Peripheral Artery Disease III: Interprofessional Care
11
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
11
Heart Failure VI: Adjunct Therapies
16
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
16


